Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation

Inclusion Criteria: 1. Male or female NVAF patients, who need anticoagulant therapy at least 3 months 2. Age ≥20 years, 3. Creatinine clearance rate ≥ 15 ml/min 4. Sign a written informed consent form (ICF) for participating in the study 5. No simultaneous participation in any interventional study Exclusion Criteria: 1. Patients with the Valve replacement 2. Patients with valvular atrial fibrillation 3. Mild and severe anemia patients 4. CrCl\<15ml/min 5. Patients on dialysis, risk of bleeding, taking antiplatelet drugs, or taking other anticoagulants 6. Contraindicated to Edoxaban. 7. Life expectancy \< 6 months. 8. Hypertension defined as systolic and/or diastolic blood pressure \> 95th age percentile or poorly controlled hypertension 9. Hepatic disease which is associated either: with coagulopathy leading to a clinically relevant bleeding risk, or alanine transaminase (ALT) \> 5x upper level of normal (ULN), or total bilirubin \> 2x ULN with direct bilirubin \> 20% of the total. 10. Active bleeding or high risk for bleeding contraindicating anticoagulant therapy. For example： * a history of intracranial, intraocular, intraspinal, retroperitoneal, or traumatic intra-articular bleeding * gastrointestinal bleeding during the prior year * peptic ulcer within the previous 90 days * surgery or injury requiring hospitalization within the previous 30 days * hemoglobin \<9 g/dl or a platelet count \<50×109/L * active bleeding at registration * any procedure associated with bleeding planned to occur during the treatment period 11. Urine pregnancy test positive if female 12. Inability to cooperate with the study procedures 13. Participation in a study with an investigational drug or medical device within 30 days prior to screening 14. Additional exclusion criteria included, but were not limited to: * cerebral infarction or transient ischemic attack within the past 30 days * comorbid rheumatic valvular disease * comorbid infective endocarditis or atrial myxoma * evidence of thrombus in the left ventricle or atrium, or hereditary tendency for thrombus formation scheduled electrical or pharmacological defibrillation during the treatment period * acute myocardial infarction, or unstable angina * a diagnosis of active malignant tumor or cancer treatment within the past 5 years * previous treatment with Edoxaban